INTRODUCTION
============

Opioid dependence is a significant public health problem in the United States ([@R20]), with estimated annual economic costs exceeding \$55 billion as a result of lost workplace productivity and increased healthcare and criminal justice expenditures ([@R2]). However, successful treatment of opioid dependence using opioid-substitution therapy with long-acting opioids such as buprenorphine can substantially reduce these costs and improve patients' functioning ([@R13]; [@R25]). A retrospective study of 2 large US health systems found that mean total healthcare costs for opioid-dependent patients receiving buprenorphine treatment and counseling were less than half of the costs for patients receiving little or no treatment (\$13,578 vs \$31,035) ([@R13]).

Effective pharmacologic maintenance treatment approaches reduce opioid cravings, prevent withdrawal, improve treatment retention, and reduce participation in risky behaviors (eg, injection drug use) ([@R6]; [@R15]). Patient engagement in psychosocial and behavioral counseling is recommended in addition to pharmacologic treatment to promote healthy behaviors and self-motivation ([@R27]). Individualized treatment plans should address factors that influence recovery, including past treatment history, living conditions, social and cultural factors, and patient acceptance and satisfaction with treatment ([@R27]). Of these factors, patient satisfaction with opioid-substitution treatment may be affected by patient perception of the convenience of treatment and sensory properties (eg, taste, mouthfeel) of medication ([@R17]; [@R16]; [@R5]). Assessing patient satisfaction with treatment is a potential target to improve adherence and maximize the clinical and societal benefits of therapy ([@R16]; [@R22], [@R23]). Although improved clinical outcomes are understandably the primary goal for mental health treatment interventions, specific patient-focused outcomes may have fundamental value as well, including the importance of patient preference when selecting treatment and patient engagement in clinical decision-making ([@R11]).

Sublingual buprenorphine and buprenorphine/naloxone (BNX) combinations are effective options for office-based treatment of opioid dependence, with a low potential for toxicity and misuse ([@R1]; [@R14]). Zubsolv (Orexo US, Inc., Morristown, NJ) is a buprenorphine/naloxone rapidly dissolving sublingual tablet formulation (BNX-RDT) with improved absorption and bioavailability that was developed as an alternative to sublingual BNX tablet and film formulations ([@R14]). This formulation incorporates sucralose and menthol to mask the bitter taste of active ingredients, has improved bioavailability compared with other sublingual BNX tablet and film formulations, and has a fast dissolution rate ([@R14]; [@R15]). A sublingual 5.7/1.4-mg dose of BNX-RDT was found to provide equivalent buprenorphine exposure and 12% lower naloxone exposure than an 8/2-mg buprenorphine/naloxone dose of a previously available BNX tablet (ie, a 30% lower dose of BNX-RDT can be used compared with the previously available BNX tablet) ([@R14]; [@R5]). In addition, the availability of multiple dose strengths of BNX-RDT (1.4/0.36, 2.9/0.71, 5.7/1.4, 8.6/2.1, and 11.4/2.9 mg) ([@R28]) might simplify dosing and allow patients to be treated with fewer tablets daily.

Although patient preference for various buprenorphine products has not yet been proven to influence clinical outcomes and prevent relapse, enhancing patient experience with buprenorphine-based medication has been posited to potentially facilitate treatment engagement ([@R4]; [@R3]; [@R21]), which, in turn, could influence retention in treatment ([@R22]). Regarding preference data for the BNX formulations, in a study of healthy volunteers, BNX-RDT received higher ratings for taste and overall acceptability than BNX film and a previously available BNX tablet formulation ([@R5]). In addition, participants reported preferable taste and greater overall acceptability compared with the previously available BNX tablet, and preferable mouthfeel and less unpleasant aftertaste compared with sublingual BNX film ([@R5]). Overall, 89% and 77% of participants preferred BNX-RDT over BNX film and the previously available BNX tablet, respectively ([@R5]).

Whereas data from healthy volunteers may suggest preferable characteristics of BNX-RDT ([@R5]), clinical data with opioid-dependent patients are needed for further validation. Although several studies assessed the efficacy and safety of switching from generic buprenorphine to BNX formulations ([@R4]; [@R16]; [@R18]), clinical evidence is lacking with regard to switching between different BNX formulations, including BNX-RDT, which has a 5.7/1.4 mg buprenorphine/naloxone ratio as determined by a pharmacokinetic bioequivalence trial rather than clinical outcome data ([@R5]). Hence, comparative data between BNX products are needed to evaluate patient preference and also clinical efficacy. Such data are of paramount importance for patients and clinicians to make informed decisions when selecting treatment. To address these gaps in treatment knowledge, the current study examined the effect of switching treatments between 2 sublingual BNX formulations---BNX film and BNX-RDT---on treatment efficacy, safety, and preference ratings in opioid-dependent patients participating in the Induction, STabilization, Adherence and Retention Trial (ISTART).

METHODS
=======

Study Design
------------

The ISTART was a prospective, randomized, parallel-group, multicenter, noninferiority trial conducted at 43 centers in the United States, from August 2013 to April 2014; the primary efficacy and key secondary outcomes of ISTART were previously reported ([@R7]). The study comprised a 2-day induction phase and a 20-day stabilization phase (Fig. [1](#F1){ref-type="fig"}). Visits were scheduled on days 1, 2, 3, 4, 8, 15, and 22 (final study visit). Opioid-dependent patients were randomly assigned to induction with either BNX-RDT or generic buprenorphine tablets for 2 days. On day 3, patients allocated to buprenorphine were switched to BNX film, whereas those allocated to BNX-RDT continued on the same treatment. On day 15, patients receiving BNX film were switched to BNX-RDT, and those on BNX-RDT were switched to film. The current study presents secondary analysis data focusing on the phase after the transition between products at day 15. Although patients were stabilized on treatment with sublingual BNX-RDT or BNX film during the first 15 days of the study, patients were evaluated for an additional 6 days after the treatment switch for clinical symptoms of withdrawal, which was anticipated to be an adequate timeframe for such symptoms to occur. Measuring withdrawal after the switch was especially important for patients switched to the higher-bioavailability BNX-RDT formulation, which has a lower dose (derived from pharmacokinetic data) and, until the present study, had not been evaluated in a clinical setting with opioid-dependent patients.
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This study was conducted in accordance with the Declaration of Helsinki, and in compliance with the International Council on Harmonisation Good Clinical Practice guidelines and all applicable laws and regulations. The study protocol was approved by an institutional review board at each site, and all patients provided written informed consent. The study is registered on ClinicalTrials.gov (identifier NCT01908842).

Patients
--------

Adults aged 18 to 65 years and in generally good health, who met *Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision* (DSM-IV-TR) criteria for opioid dependence in the past 12 months, were eligible if they agreed to abstain from opioid use and other addictive drugs, and if they demonstrated at least mild withdrawal symptoms defined as a Clinical Opiate Withdrawal Scale (COWS) score at least 9 predose on day 1. Eligibility also required a buprenorphine-negative urine drug screen, and for female participants, a negative urine pregnancy test and agreement to use a reliable method of contraception. Any prescribed opioids for pain were withdrawn before induction after obtaining clearance from the prescribing physician.

Patients could not have a serious, untreated axis I DSM-IV-TR psychiatric comorbidity or be considered at risk for suicide; a clinically significant medical disorder or condition that would compromise participant safety or the validity of study results; or a tongue or oral deformity that might affect absorption of study drug. Other exclusion criteria included use of generic buprenorphine monotherapy within 90 days or methadone at a daily dose above 30 mg within the past week, any methadone within 30 hours of initial study treatment, or any medication or product with strong cytochrome P450 3A4 inhibition or induction properties within 14 days of screening.

Study Treatment
---------------

Study treatment consisted of BNX-RDT (5.7/1.4 or 1.4/0.36 mg; Zubsolv), BNX sublingual film (8/2 or 2/0.5 mg; Suboxone film, Reckitt Benckiser, Richmond, VA), and generic buprenorphine sublingual tablets (8 or 2 mg; Roxane Laboratories, Columbus, OH). Generic buprenorphine was selected as the comparator agent for induction as it was the only product approved for use as induction therapy when the study was designed and initiated. On days 1 and 2, patients received a fixed dose of BNX-RDT (5.7/1.4 mg on day 1 and 5.7/1.4 or 11.4/2.8 mg on day 2) or generic buprenorphine (8 mg on day 1 and 8 or 16 mg on day 2). On day 3, patients in the generic buprenorphine group were switched to BNX film. During the open-label stabilization period (days 3--22), individual daily dosing regimens could be titrated to a bioequivalent maximum of 17.1/4.2 mg for BNX-RDT and 24/6 mg for BNX film based on clinical symptoms. On day 15, patients switched treatments according to a fixed conversion factor of 5.7 to 8 mg based on the corresponding dose strengths of BNX-RDT and BNX film; patients were switched to a dose commensurate to the dose they were taking in the previous week. Patients continued on the switched treatment though day 22.

Endpoints
---------

The endpoints of focus for the current study were secondary efficacy endpoints assessed during days 15 to 22 of the ISTART. These included retention in treatment at each visit, opioid withdrawal assessed using the COWS (scored from 0 to 48: \<5 = none; 5--12 = mild; 13--24 = moderate; 25--36 = moderately severe; \>36 = severe withdrawal symptoms) ([@R26]) and the Subjective Opiate Withdrawal Scale (SOWS; scored from 0 to 64; lower score is indicative of less withdrawal) ([@R8]), and opioid cravings assessed using a VAS ranging from 0 ("no cravings") to 100 ("most intensive craving I have ever had"). COWS, SOWS, and VAS cravings assessments were performed before dosing on treatment visit days and additionally at 0.5, 1.5, 3, and 6 hours after dosing on day 1. Before treatment on day 22, patients completed a dichotomous preference assessment questionnaire comparing BNX-RDT and BNX film in terms of taste, mouthfeel, ease of administration, and overall preference. The coprimary efficacy endpoints in the ISTART were retention in treatment at days 3 and 15, defined as the number of patients who received treatment on days 3 and 15.

Safety evaluations included assessment of adverse events (AEs) at all visits from day 1 through the end of the study and patient assessment of constipation symptoms (PAC-SYM; measures 12 symptoms in 3 domains \[abdominal, rectal, stool\] scored from 0 to 4; lower score is favorable) at screening and on days 15 and 22.

Statistics
----------

Efficacy assessments were performed using the full analysis population, which was defined as all patients who were randomized and had at least 1 dose of study medication. Safety assessments were performed using the safety population, which was defined as all patients who had at least 1 dose of study medication. As the coprimary endpoints of ISTART were retention in treatment at days 3 and 15 ([@R7]), the handling of dropouts or missing data was not an issue. All secondary efficacy analyses were based on observed data in the full analysis population.

Data regarding patient demographics and baseline clinical characteristics were summarized descriptively; no formal statistical testing was performed. Patient preference for BNX sublingual tablets versus BNX film in terms of taste, mouthfeel, ease of administration, and overall preference was assessed after the last treatment period using McNemar test. Changes from baseline in COWS and SOWS total scores and VAS cravings assessments were tabulated, but not formally analyzed. AEs were coded using the Medical Dictionary for Regulatory Activities (version 16.0). PAC-SYM results were evaluated using summary statistics for observed values and changes from baseline at days 15 and 22.

RESULTS
=======

Patients
--------

Patient demographic and baseline characteristics were similar between the 2 treatment arms (Table [1](#T1){ref-type="table"}). The study cohort had a mean age of 35.6 years; most patients were men (59.6%) and white (83.1%) with a mean reported duration of opioid dependence of 10.6 years.

A total of 758 opioid-dependent patients were randomly assigned to induction with BNX-RDT (n = 383) or generic buprenorphine (n = 375) (Fig. [2](#F2){ref-type="fig"}). Of these, 701 patients entered the open-label stabilization phase on day 3 (BNX-RDT, n = 357; BNX film, n = 344). From day 3 to day 15, 135 patients (19.3%; BNX-RDT, n = 70; BNX film, n = 65) withdrew from the study.
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At day 15, 287 patients switched from BNX-RDT to BNX film, and 279 patients switched from BNX film to BNX-RDT. From day 15 to day 22, 25 patients (8.7%) who were switched to BNX film and 17 patients (6.1%) who were switched to BNX-RDT withdrew from the study.

Doses of Study Treatment
------------------------

Based on bioequivalent doses, mean daily doses for both formulations were comparable at day 15 and day 22. For BNX-RDT, the mean daily dose was 10.8 mg at day 15 (15.2 mg film equivalent based on the 8.0:5.7 mg film-to-tablet ratio) and 11.3 mg (15.9 mg film equivalent) at day 22. The mean daily dose of BNX film was 15.9 mg at day 15 and 16.0 mg at day 22.

Patient Preference
------------------

Among patients who had received treatment with 1 formulation up to day 15 and with the other formulation from day 15 to 22, preference assessment results significantly favored BNX-RDT (*P* \< 0.0001 for each comparison; Fig. [3](#F3){ref-type="fig"}). For the overall preference assessment, 70.2% (346/493) of patients preferred BNX-RDT and 29.8% (147/493) preferred BNX film (*P* \< 0.0001).
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Opioid Withdrawal Symptoms
--------------------------

Both treatments similarly reduced opioid withdrawal as assessed by COWS total scores during induction, stabilization, and after switching (Fig. [4](#F4){ref-type="fig"}A). Similar COWS total scores at day 15 and day 22 in both treatment groups indicated an absence of emergent withdrawal symptoms after switching treatments. At day 15, mean ± standard deviation (SD) COWS total scores were 4.1 ± 3.5 with BNX-RDT and 3.7 ± 3.4 with BNX film, corresponding to mean ± SD changes from baseline of −10.7 ± 4.9 and −11.2 ± 4.8, respectively. At day 22, mean ± SD COWS total scores were 3.3 ± 3.4 for patients switched to BNX film and 3.4 ± 3.3 for patients switched to BNX-RDT, indicating a lack of emergent withdrawal for both groups (COWS \< 5) ([@R26]) and corresponding to mean ± SD changes from baseline of −11.5 ± 4.8 and −11.3 ± 5.0, respectively.

![Mean time profile of (A) COWS total score, (B) SOWS total score, and (C) VAS score for opioid craving by treatment group (full analysis population). BNX, buprenorphine/naloxone; COWS, Clinical Opiate Withdrawal Scale; SOWS, Subjective Opiate Withdrawal Scale; VAS, visual analog scale.](adm-10-122-g004){#F4}

Similarly, reductions in opioid withdrawal over time as assessed by SOWS total scores were comparable between treatment before and after switching (Fig. [4](#F4){ref-type="fig"}B), further demonstrating a lack of emergent withdrawal symptoms with both formulations after switching treatments. At day 15, mean ± SD SOWS total scores were 7.2 ± 7.7 with BNX-RDT and 6.7 ± 8.1 with BNX film, corresponding to mean ± SD changes from baseline of −24.1 ± 13.8 and −26.6 ± 13.8, respectively. At day 22, mean ± SD SOWS total scores were 7.3 ± 9.2 for patients switched to BNX film and 6.8 ± 7.9 for patients switched to BNX-RDT, representing mean ± SD changes from baseline of −25.6 ± 13.4 and −24.5 ± 14.5, respectively.

Opioid Cravings
---------------

Both treatments similarly reduced opioid cravings with a time course comparable to that for the reduction in opioid withdrawal symptoms (Fig. [4](#F4){ref-type="fig"}C). At day 15, mean ± SD VAS craving scores were 21.6 ± 23.9 with BNX-RDT and 19.1 ± 23.4 with BNX film, corresponding to mean ± SD changes from baseline of −46.8 ± 30.7 and −54.2 ± 28.7, respectively. At day 22, mean ± SD craving scores were 20.9 ± 23.8 for patients switched to BNX film and 20.2 ± 22.9 for patients switched to BNX-RDT, corresponding to mean ± SD changes from baseline of −52.3 ± 28.8 and −49.0 ± 30.1, respectively.

Safety
------

During the entire open-label phase, the incidence of treatment-related AEs assessed at the onset of the AE was 8.3% (53/635) with BNX-RDT and 7.5% (47/630) with BNX film. Of treatment-related AEs occurring in patients assessed at the onset of the AE through the end of the study, constipation occurred in 1.9% (12/635) of patients receiving BNX-RDT and 2.2% (14/630) of patients receiving BNX film. During the open-label stabilization phase from days 3 to 15, the incidences of treatment-related AEs in the BNX-RDT and BNX film groups were 11.8% (42/357) and 10.8% (37/344), respectively (*P* = 0.67). The most common AEs were constipation (2.8% vs 3.5%) and headache (1.4% vs 2.0%).

Mean changes from baseline in PAC-SYM scores at day 15 and day 22, respectively, were −0.45 and −0.37 for patients stabilized on BNX-RDT, and −0.38 and −0.46 for patients stabilized on BNX film. These results indicate that, on average, constipation symptoms improved over the course of the study with both treatments.

There were no treatment-related serious AEs with either treatment. However, after the day 15 switch, 1 patient in the BNX film group experienced a serious AE of increased transaminase levels deemed unrelated to study medication. This serious AE was considered moderate in intensity and resolved after 6 days.

DISCUSSION
==========

This study indicates that clinical efficacy and safety are maintained when opioid-dependent patients entering maintenance switch between BNX-RDT and BNX film formulations after completion of a 15-day stabilization period. The findings provide important practical information needed by clinicians and patients when considering a transition between BNX formulations during maintenance treatment, particularly as the more recently available BNX-RDT formulation is a departure from other previously and currently available BNX products in terms of per tablet dose, physical characteristics (eg, taste), absorption, and bioavailability ([@R14]; [@R5]). Clinicians and patients alike may question if the 5.7:8.0 mg conversion factor, established based on bioequivalence data, is clinically comparable. Our findings indicate clinical comparability based on continued reduction in opioid withdrawal and cravings. Although most participants preferred the tablet formulation, additional data are needed regarding the potential impact on adherence and longer-term patient outcomes.

Regarding comparable efficacy data, of patients who switched treatments at day 15, more than 90% of patients in both groups completed through day 22 of treatment after switching. Although no formal statistical analysis was performed for patient discontinuations, rates were numerically similar in both treatment groups after the switch (8.7% and 6.1% of patients who switched from BNX-RDT to BNX film or BNX film to BNX-RDT, respectively). Opioid withdrawal and craving results were similar for both formulations at day 15 (before switching), with no indication of a change in symptoms by day 22 after the switch from either product. By day 15, mean COWS total scores in both treatment groups indicated that, on average, patients were withdrawal-free (ie, mean total score \<5). Safety results showed that AEs through the end of the study were similar in frequency to AEs recorded from days 3 to 15 before the switch. The incidence of constipation-related AEs was low, and on average, preexisting constipation symptoms improved from baseline to the end of the study for both medications. In addition, titrated doses remained essentially the same based on bioequivalence for both groups from day 15 to day 22, indicating that the 5.7 to 8-mg conversion ratio is appropriate when switching between products.

The efficacy data provide clinical evidence that doses determined to be bioequivalent in a previous pharmacokinetic study ([@R5]) are also clinically comparable when transitioning between products (ie, a 5.7/1.4-mg buprenorphine/naloxone dose of BNX-RDT is clinically similar to an 8/2-mg buprenorphine/naloxone dose of BNX sublingual film). Thus, it is noteworthy that comparable efficacy can be expected when patients are treated with an approximately 30% lower dose of BNX-RDT than of BNX film. In clinical practice, patients might express concerns about switching to a lower dose ([@R12]). To the extent that expectations can influence perceived drug effects ([@R9]; [@R10]; [@R24]), the findings from the current study may help alleviate patient concerns about a transition to a lower bioequivalent dose of the tablet formulation and thus avoid a potentially unnecessary dose increase. Although the study indicates efficacy and tolerability when changing between products, practitioners should continually monitor patients for signs of overmedication, withdrawal, or underdosing, as dose adjustments may be necessary when switching treatments ([@R19]; [@R28]).

A substantial majority (\>70%) of patients who had experience with both BNX formulations reported that they preferred BNX-RDT over BNX film in terms of taste, mouthfeel, ease of administration, and overall acceptability. Previously reported preference data on sublingual buprenorphine-containing products have been mixed. Although patients reported preferring the first approved BNX tablet formulation (Suboxone) over buprenorphine alone in terms of taste, size, and sublingual dissolution time ([@R4]), the palatability of the first BNX tablet formulation received less favorable ratings in a separate study ([@R16]). In that study of patients who switched from a buprenorphine tablet to a BNX tablet formulation, approximately 50% of participants reported disliking the sensory properties (taste, color, odor, and mouthfeel) of the BNX tablet.

Previous studies have demonstrated that increased adherence may result in greater clinical benefits, lower relapse rates, and reduced direct healthcare expenditures ([@R16]; [@R22], [@R23]). Further study in a real-world setting with longer treatment duration is needed to examine if strong patient preference for a BNX formulation will improve adherence and result in better clinical outcomes.

There are several possible limitations of this study. Firstly, patient familiarity with the BNX film formulation could have biased outcomes; however, it seems likely that any bias introduced by previous experience with BNX film might favor that formulation over the higher-bioavailability BNX-RDT. Secondly, this study was conducted at selected clinical research sites, and findings may not be generalizable to all office-based practices. Finally, study treatment was open-label rather than blinded, which was necessary to allow for assessments of patient preference.

CONCLUSIONS
===========

These data indicate that among opioid-dependent patients receiving BNX maintenance treatment, transition between BNX film and BNX-RDT may be undertaken with comparable efficacy and safety. Patient discontinuation rates during the treatment switch phase were similar for each group, and the transition between both products was associated with continued withdrawal suppression, craving reduction, and similar safety profiles. Thus, there is no apparent clinical rationale from the findings indicating limitations when switching patients between the film and tablet products tested in the study. Most patients preferred BNX-RDT over BNX film; however, further study is required regarding the clinical implications of patient preference. Overall, the study provides important data to guide clinical decision-making during buprenorphine maintenance treatment, and hopefully will help mitigate the public health burden of opioid use disorder.
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###### 

Demographics and Baseline Clinical Characteristics^∗^

  Characteristics                                                                                      BNX-RDT (n = 383)   Buprenorphine/BNX Film (n = 375)   All Patients (N = 758)
  ---------------------------------------------------------------------------------------------------- ------------------- ---------------------------------- ------------------------
  Age, mean (SD), y                                                                                    35.7 (11.26)        35.6 (11.28)                       35.6 (11.26)
  Sex, n (%)                                                                                                                                                  
   Male                                                                                                216 (56.4)          236 (62.9)                         452 (59.6)
   Female                                                                                              167 (43.6)          139 (37.1)                         306 (40.4)
  Race, n (%)                                                                                                                                                 
   White                                                                                               318 (83.0)          312 (83.2)                         630 (83.1)
   Black/African American                                                                              51 (13.3)           49 (13.1)                          100 (13.2)
   Other or not recorded                                                                               14 (3.7)            14 (3.7)                           28 (3.7)
  Duration of opioid dependence, mean (SD), y                                                          10.7 (9.57)         10.5 (9.01)                        10.6 (9.29)
  Self-report of prior substance use over past 30 d, n (%)[^†^](#TF1-2){ref-type="table-fn"}                                                                  
   Heroin                                                                                              212 (55.5)          199 (53.4)                         411 (54.4)
   Methadone                                                                                           51 (13.4)           48 (12.9)                          99 (13.1)
   Buprenorphine                                                                                       41 (10.7)           29 (7.8)                           70 (9.3)
   Other opioids/analgesics                                                                            240 (62.8)          235 (63.0)                         475 (62.9)
  Self-report of prior substance use in patient\'s lifetime, n (%)[^†^](#TF1-2){ref-type="table-fn"}                                                          
   Heroin                                                                                              235 (61.8)          236 (63.4)                         471 (62.6)
   Methadone                                                                                           127 (33.5)          129 (34.7)                         256 (34.1)
   Buprenorphine                                                                                       125 (32.9)          108 (29.0)                         233 (31.0)
   Other opioids/analgesics                                                                            304 (79.8)          288 (77.4)                         592 (78.6)

^\*^Patient demographics and baseline clinical characteristic data were summarized descriptively; no formal statistical testing was performed.

^†^Percentages based on number of patients with available responses.

BNX-RDT, buprenorphine/naloxone rapidly dissolving sublingual tablet formulation; SD, standard deviation.
